Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Forbright Inc (FRBT)
NASDAQFinancialsBanks - DiversifiedSnapshot 2026-11-04
$19.50+2.42%
Close 2026-11-04 · 1-day change
NASDAQFinancialsBanks - DiversifiedSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Oct 4, 2026.
Next-FY EPS estimate change · 30 days
2.39 → 2.51 EPS · FY ending Dec 31, 2027 · 3 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 3 to 3; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for FRBT yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
analyst upgrades | A supporting condition in Forbright Inc's published investment case. The stated target is >=1 upgrade. | Intact | no analyst upgrades in the next quarter | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
FRBT is a regional banking business with a growth-and-efficiency thesis, rather than a clearly established durable compounder or turnaround. The thesis is still insufficiently tested: the latest quarter showed progress, but the evidence snapshot has low overall confidence and little recent performance history.
The available evidence does not provide a valuation level or clear market expectations, so it is not possible to describe FRBT as cheap, fair, or expensive versus peers. Fragility is rated low, but that alone does not show what expectations are already reflected.
Near term, management’s stated focus areas showed progress: loans grew, the efficiency ratio improved, and digital deposits increased, though deposit growth was driven by promotions and planned AI capabilities remain future work. Recent earnings history is a concern: FRBT missed in July, and the evidence notes misses across recent quarters, despite the latest earnings release on October 29.
Over the next one to three years, the thesis depends on whether loan and fee growth, expense control, and deposit capabilities continue to improve. Near term, Federal Reserve rate decisions and earnings signals from JPM, BAC, and HSBC could strengthen or weaken the sector backdrop for FRBT.
FRBT has measurable operating progress, but its multi-year thesis remains uncertain because recent earnings have been weak and the evidence base is limited. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| The sale of branches to Trustar Bank enhances liquidity. |
| Intact |
| branch sale proceeds fall below $19 million |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
earnings per share growth | Analysts expect earnings to grow to $2.39 per share in 2027. | Intact | EPS falls below $1.09 next fiscal year | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Oct 4, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$2.39 → $2.51 · observed estimates
$0.42B → $0.42B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-09-07 | $2.39 | $419,690,000 | 3 / 4 |
| 2026-09-08 | $2.39 | $419,690,000 | 3 / 4 |
| 2026-09-09 | $2.39 | $419,690,000 | 3 / 4 |
| 2026-09-10 | $2.39 | $419,690,000 | 3 / 4 |
| 2026-09-11 | $2.39 | $419,690,000 | 3 / 4 |
| 2026-09-12 | $2.39 | $419,690,000 | 3 / 4 |
| 2026-09-13 | $2.39 | $419,690,000 | 3 / 4 |
| 2026-09-14 | $2.39 | $419,690,000 | 3 / 4 |
| 2026-09-15 | $2.39 | $419,690,000 | 3 / 4 |
| 2026-09-16 | $2.39 | $419,690,000 | 3 / 4 |
| 2026-09-17 | $2.39 | $419,690,000 | 3 / 4 |
| 2026-09-18 | $2.39 | $419,690,000 | 3 / 4 |
| 2026-09-19 | $2.39 | $419,690,000 | 3 / 4 |
| 2026-09-20 | $2.39 | $419,690,000 | 3 / 4 |
| 2026-09-21 | $2.39 | $419,690,000 | 3 / 4 |
| 2026-09-22 | $2.39 | $419,690,000 | 3 / 4 |
| 2026-09-23 | $2.39 | $419,690,000 | 3 / 4 |
| 2026-09-24 | $2.39 | $419,690,000 | 3 / 4 |
| 2026-09-25 | $2.39 | $419,690,000 | 3 / 4 |
| 2026-09-26 | $2.39 | $419,690,000 | 3 / 4 |
| 2026-09-27 | $2.39 | $419,690,000 | 3 / 4 |
| 2026-09-28 | $2.39 | $419,690,000 | 3 / 4 |
| 2026-09-29 | $2.39 | $419,690,000 | 3 / 4 |
| 2026-09-30 | $2.39 | $419,690,000 | 3 / 4 |
| 2026-10-01 | $2.39 | $419,690,000 | 3 / 4 |
| 2026-10-02 | $2.39 | $419,690,000 | 3 / 4 |
| 2026-10-03 | $2.39 | $419,690,000 | 3 / 4 |
| 2026-10-04 | $2.39 | $419,690,000 | 3 / 4 |
| 2026-10-05 | $2.39 | $419,690,000 | 3 / 4 |
| 2026-10-06 | $2.39 | $419,690,000 | 3 / 4 |
| 2026-10-07 | $2.39 | $419,690,000 | 3 / 4 |
| 2026-10-08 | $2.46 | $422,900,000 | 3 / 3 |
| 2026-10-09 | $2.46 | $422,900,000 | 3 / 3 |
| 2026-10-10 | $2.46 | $422,900,000 | 3 / 3 |
| 2026-10-11 | $2.46 | $422,220,000 | 3 / 3 |
| 2026-10-12 | $2.46 | $422,220,000 | 3 / 3 |
| 2026-10-13 | $2.46 | $422,220,000 | 3 / 3 |
| 2026-10-14 | $2.46 | $422,220,000 | 3 / 3 |
| 2026-10-15 | $2.46 | $422,220,000 | 3 / 3 |
| 2026-10-16 | $2.46 | $422,220,000 | 3 / 3 |
| 2026-10-17 | $2.46 | $422,220,000 | 3 / 3 |
| 2026-10-18 | $2.46 | $422,220,000 | 3 / 3 |
| 2026-10-19 | $2.46 | $422,220,000 | 3 / 3 |
| 2026-10-20 | $2.46 | $422,220,000 | 3 / 3 |
| 2026-10-21 | $2.46 | $422,220,000 | 3 / 3 |
| 2026-10-22 | $2.46 | $422,220,000 | 3 / 3 |
| 2026-10-23 | $2.46 | $422,220,000 | 3 / 3 |
| 2026-10-24 | $2.46 | $422,220,000 | 3 / 3 |
| 2026-10-25 | $2.46 | $422,220,000 | 3 / 3 |
| 2026-10-26 | $2.46 | $422,220,000 | 3 / 3 |
| 2026-10-27 | $2.46 | $422,220,000 | 3 / 3 |
| 2026-10-28 | $2.46 | $422,220,000 | 3 / 3 |
| 2026-10-29 | $2.46 | $422,220,000 | 3 / 3 |
| 2026-10-30 | $2.46 | $422,220,000 | 3 / 3 |
| 2026-10-31 | $2.46 | $422,220,000 | 3 / 3 |
| 2026-11-01 | $2.46 | $422,220,000 | 3 / 3 |
| 2026-11-02 | $2.46 | $422,220,000 | 3 / 3 |
| 2026-11-03 | $2.46 | $422,220,000 | 3 / 3 |
| 2026-11-04 | $2.51 | $422,220,000 | 3 / 3 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 5 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 2 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.